☆ 4.4 Review

Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications

CURRENT ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Review Biochemistry & Molecular Biology

Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance

Danilo De Novellis et al.

Summary: CD38 and B-cell maturation antigens (BCMAs) are highly expressed on neoplastic plasma cells in multiple myeloma (MM), making them attractive targets for therapy. Anti-CD38 monoclonal antibodies, like daratumumab and isatuximab, have shown significant efficacy in MM treatment by inducing plasma cell apoptosis through various mechanisms. BCMA is also a promising target in MM, with different therapeutic strategies being explored, including antibody-drug conjugates, bispecific T cell engagers, and chimeric antigen receptor-modified T cell therapies. However, resistance mechanisms to these agents have been identified, highlighting the need for further research and development.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Oncology

A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors

Victor Moreno et al.

Summary: Mitazalimab, a human monoclonal antibody targeting CD40, was evaluated in this study for anti-tumor immunotherapy. The results demonstrated its manageable safety profile and pharmacokinetic/pharmacodynamic properties, suggesting its potential as a treatment option for solid malignancies.

INVESTIGATIONAL NEW DRUGS (2023)

Add to Collection

Review Oncology

Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives

Piotr Kulig et al.

Summary: Multiple myeloma (MM) is the second most common hematological malignancy and the prognosis has significantly improved with the development of novel treatment regimens. Immunomodulatory drugs (IMiDs) have been a milestone in MM therapy, but the majority of patients eventually become resistant to these drugs. This review focuses on LEN resistance mechanisms and strategies for treating LEN-refractory disease.

CANCERS (2023)

Add to Collection

Review Oncology

Experts' consensus on the definition and management of high risk multiple myeloma

Chiara Marcon et al.

Summary: This study conducted a survey to identify additional clinical and biological risk factors for high risk multiple myeloma (HRMM) and to evaluate if the management of multiple myeloma should change based on the risk category. The survey found a consensus regarding the inclusion of chromosome 1 abnormality, TP53 mutation or deletion, circulating plasma cells, and extramedullary plasmacytomas in the definition of HRMM. However, there was no consensus on the definition of double hit MM and the application of treatment strategies based on the risk category.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Hematology

Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma

James R. R. Berenson et al.

Summary: This study evaluated the efficacy of combination therapy with ruxolitinib and methylprednisolone for multiple myeloma patients. The results showed that this treatment regimen demonstrated significant clinical activity among heavily-treated patients and achieved responses in patients with high-risk cytogenetics.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Review Hematology

Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies

Daisuke Minakata et al.

Summary: This study is a systematic review and network meta-analysis (NMA) of randomized trials in patients with relapsed and/or refractory (RR) multiple myeloma (MM). The study found that daratumumab, lenalidomide, and dexamethasone are the best treatment options for RRMM.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Review Oncology

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse

Parva Bhatt et al.

Summary: Multiple myeloma is an incurable disease with heterogeneous relapses. Personalized therapeutic choices based on risk stratification and cytogenetic alterations aim to achieve long-term remissions. This scoping review covers available therapies in relapsed/refractory multiple myeloma, including immunomodulatory agents, proteasome inhibitors, monoclonal antibodies, traditional chemotherapy, and Venetoclax. It also discusses special situations during relapse and the potential of CAR-T therapy, BITE, and CELMoDs.

CURRENT ONCOLOGY (2023)

Add to Collection

Article Oncology

A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma

Barry Paul et al.

Summary: Magrolimab is a monoclonal antibody that blocks the CD47 signal on tumor cells. CD47 is overexpressed in multiple myeloma and contributes to its development. Preclinical studies have shown that blocking CD47 activates macrophages, leading to the elimination of myeloma cells. This phase II study investigates the combination of magrolimab with standard myeloma therapies in patients with relapsed/refractory MM.

FUTURE ONCOLOGY (2023)

Add to Collection

Review Immunology

The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells

Claudia Giannotta et al.

Summary: Myeloid derived suppressor cells (MDSC) have significant roles in regulating immune homeostasis and immune responses, especially in cancer. MDSC interact with cancer cells in the tumor microenvironment through various mechanisms such as producing soluble factors, expressing inhibitory molecules, rewiring metabolism, and releasing exosomes. The relationship between MDSC and tumor cells leads to immune evasion and cancer growth. In multiple myeloma (MM), MDSC play a major role in creating a tumor-promoting microenvironment. This minireview discusses the interplay between MDSC and MM microenvironment, as well as potential strategies to target MDSC.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Oncology

A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma

Satoko Kakiuchi-Kiyota et al.

Summary: Despite the current incurability of multiple myeloma (MM), the novel treatment, RO7297089, shows potential as an effective and well-tolerated therapy. By targeting BCMA and CD16A, RO7297089 induces lysis of MM cells and has a favorable safety profile, as evidenced by in vitro cytokine release and animal studies.

LEUKEMIA (2022)

Add to Collection

Review Oncology

High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions

Patrick Hagen et al.

Summary: Multiple myeloma is a malignant plasma cell disorder that occurs in late life. Despite the use of various risk stratification systems in clinical practice, there is still a lack of consensus on the definition of high risk disease. Establishing a unified definition of high risk disease is important for guiding treatment approaches and research requirements.

BLOOD CANCER JOURNAL (2022)

Add to Collection

Article Oncology

Tumor-associated macrophages regulate the function of cytotoxic T lymphocyte through PD-1/PD-L1 pathway in multiple myeloma

Jiangbo Zhang et al.

Summary: This study found that tumor-associated macrophages (TAMs) were increased in multiple myeloma (MM) patients, which participated in the immune escape process of MM cells and inhibited the function of cytotoxic T lymphocytes (CTLs).

CANCER MEDICINE (2022)

Add to Collection

Review Oncology

Tumor-associated macrophages in multiple myeloma: advances in biology and therapy

Jennifer Sun et al.

Summary: MM is a cancer of plasma cells in the bone marrow, with the tumor microenvironment playing a critical role in disease progression. TAMs in the TME have been found to support tumor survival and chemoresistance, highlighting the importance of exploring macrophage-targeted immunotherapy in MM treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Review Medicine, General & Internal

The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value

Vanessa Desantis et al.

Summary: Multiple myeloma relies on the bone marrow microenvironment for its development, and the immune regulation of the microenvironment may contribute to tumor cell escape and drug resistance. Besides traditional treatments, new strategies aim to restore the immune balance by targeting key components of the immune regulation process. Immune checkpoints and specific proteins have been identified as important targets for immunotherapy.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Hematology

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma

Sarah Gooding et al.

Summary: The acquisition of a multidrug refractory state is a major cause of mortality in myeloma. Previous studies have found a relationship between cereblon protein (CRBN) and immunomodulatory drugs (IMiDs) resistance, but no genetic mutations associated with IMiDs resistance have been identified. This study identified two genes, COPS7B and COPS8, in the chromosome region 2q37, which are associated with IMiDs resistance. This region may serve as a potential clinical marker for IMiDs resistance.

BLOOD (2022)

Add to Collection

Article Oncology

High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments

Nicolas Fernandez et al.

Summary: This study identifies three distinct immunophenotypic groups in smoldering myeloma patients through immune profiling analysis. The findings suggest that the functional states of the bone marrow microenvironment may contribute to disease stability or progression.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

Add to Collection

Review Oncology

Tumor-Associated Macrophages and Related Myelomonocytic Cells in the Tumor Microenvironment of Multiple Myeloma

Samuel S. Y. Wang et al.

Summary: Multiple myeloma (MM) is a common blood cancer that remains incurable. The tumor microenvironment plays a crucial role in MM pathogenesis and treatment response. Tumor-associated macrophages, myeloid-derived suppressor cells, and dendritic cells are important components of the MM tumor microenvironment. Understanding the biology of these cells and utilizing novel technologies may impact future treatment strategies for MM.

CANCERS (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

Macrophages as tools and targets in cancer therapy

Alberto Mantovani et al.

Summary: This review discusses the molecular mechanisms of macrophage reprogramming in the tumor microenvironment and provides an overview of macrophage-targeted therapies for cancer treatment.

NATURE REVIEWS DRUG DISCOVERY (2022)

Add to Collection

Review Oncology

A Journey through the Inter-Cellular Interactions in the Bone Marrow in Multiple Myeloma: Implications for the Next Generation of Treatments

Rosario Hervas-Salcedo et al.

Summary: In this article, we discuss the interactions between multiple myeloma cells and non-hematological and hematological immune cells in the bone marrow, highlighting their effects on disease progression and treatment resistance. Non-hematological cells in the bone marrow can secrete molecules that accelerate disease progression, while these interactions compromise the activity of immune cells, leading to immune evasion and disease progression. Understanding these interactions can help in the development of improved treatments for multiple myeloma.

CANCERS (2022)

Add to Collection

Article Oncology

Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling

Jin Wang et al.

Summary: Multiple myeloma (MM) is a disease characterized by clonal expansion of malignant plasma cells in the bone marrow. This study analyzed transcriptome data from MM patients and found that highly expressed cancer testis antigens and immune suppressive cell infiltration are associated with MM progression. The TGF-beta signature is also linked to worse outcomes in relapsed/refractory MM patients. Furthermore, patients with newly diagnosed MM can be classified into immune-low and immune-high phenotypes. The baseline tumor microenvironment status could potentially inform treatment choices for patients ineligible for stem cell transplantation and predict response to CAR-T therapy in relapsed/refractory MM patients.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Oncology

CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression

Katia Beider et al.

Summary: The bidirectional interactions between MM tumor cells and M phi result in M2 M phi polarization, CXCL13 induction, and subsequent OC activation, enhancing their ability to support bone resorption and MM progression. CXCL13 may serve as a potential novel target in MM treatment.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Add to Collection

Article Hematology

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Sarah Gooding et al.

Summary: The study found that in patients with myeloma, as the exposure to IMiD drugs increased, the frequency of CRBN abnormalities also increased gradually, with almost one-third of patients having CRBN alterations by the time they were refractory to pomalidomide (POM). These CRBN abnormalities were associated with inferior outcomes to POM in patients already refractory to lenalidomide (LEN).

BLOOD (2021)

Add to Collection

Article Oncology

Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma

Yael C. Cohen et al.

Summary: In this study, daratumumab plus cetrelimab was evaluated in patients with relapsed or refractory multiple myeloma, showing no new safety concerns. However, the potential clinical benefit of this combination remains uncertain, indicating the need for further research.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)

Add to Collection

Review Oncology

Macrophages in multiple myeloma: key roles and therapeutic strategies

Khatora S. Opperman et al.

Summary: Recent research has made significant progress in understanding the crucial functional roles played by macrophages in multiple myeloma, affecting various pathways essential for tumor initiation and progression. Therapeutic strategies targeting macrophages within the bone marrow niche show promise in the clinical setting.

CANCER AND METASTASIS REVIEWS (2021)

Add to Collection

Review Oncology

Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis

Lip Leong Chong et al.

Summary: The study evaluated the efficacy and safety of Daratumumab-based induction therapy in newly diagnosed multiple myeloma patients. Results showed improved stringent complete response rates in standard risk patients, but not in high-risk patients. Progression-free survival was improved in standard risk patients, with no significant benefit observed in high-risk patients.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Macrophages in Healing Wounds: Paradoxes and Paradigms

Luisa A. DiPietro et al.

Summary: Macrophages play a prominent role in skin wound healing, with functions including host defense and support of new tissue growth. However, the exact role of macrophages in wound healing remains elusive, as some wounds can heal well even with limited or no functional macrophages. Recent advances in understanding macrophage phenotypes and cellular plasticity in wounds may provide new insights and paradigms on macrophage function in wounds.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Chemistry, Physical

Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression

Ori Maller et al.

Summary: Stromal stiffening in malignant tumours is associated with poor treatment outcomes and increased tumour aggression. Identifying factors that regulate stromal stiffening could lead to biomarkers for patient stratification and interventions to improve outcomes. Experimental studies have shown that therapeutic targeting of tumour-associated macrophages and collagen crosslinking enzymes can reduce metastasis and stromal stiffening in aggressive breast cancer subtypes with stiff stroma. Additionally, the expression of lysyl hydroxylase 2 in the stroma has been linked to disease-specific mortality in breast cancer patients, indicating its potential as a stromal biomarker.

NATURE MATERIALS (2021)

Add to Collection

Article Immunology

PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients

Federica Costa et al.

Summary: The study found that MM and SMM patients share a similar PD-L1/PD-1 bone marrow immune profile, suggesting that SMM patients could be an interesting target for PD-L1/PD-1 inhibition therapy.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Oncology

The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression

Almudena Garcia-Ortiz et al.

Summary: Multiple myeloma is a hematologic cancer characterized by clonal proliferation of plasma cells in the bone marrow, with disease progression influenced by the tumor microenvironment created by various cells and soluble factors. Understanding the elements that control the microenvironment could lead to better-targeted therapies for this incurable disease.

CANCERS (2021)

Add to Collection

Review Cell Biology

Nurse-Like Cells and Chronic Lymphocytic Leukemia B Cells: A Mutualistic Crosstalk inside Tissue Microenvironments

Stefania Fiorcari et al.

Summary: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries, involving cooperation between genetic defects and tumor microenvironmental interactions in pathogenesis. CLL is considered addicted to the host, with crosstalk between leukemic cells and the tumor microenvironment essential for supporting CLL cell survival and proliferation.

CELLS (2021)

Add to Collection

Review Oncology

Targeting CD47 for cancer immunotherapy

Zhongxing Jiang et al.

Summary: Significant progress has been made in targeting CD47 for cancer immunotherapy in solid tumors and hematological malignancies, with a total of 46 clinical trials related to CD47 in the USA and 23 in China. Most of the trials are in early phases, and the new generation CD47 antibodies have shown promising results.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Oncology

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

M. A. Dimopoulos et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Letter Oncology

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma

Paul G. Richardson et al.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Oncology

The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages

Dimitrios Mougiakakos et al.

Summary: The bone marrow niche plays a crucial role in multiple myeloma progression, survival, and drug resistance. Myeloma-associated macrophages (MAMs) in the niche resemble M2 type, but can be reprogrammed into a tumoricidal M1 phenotype by lenalidomide through degradation of IKZF1. This shift can explain the clinical benefits observed when combining lenalidomide with therapeutic antibodies.

CANCER IMMUNOLOGY RESEARCH (2021)

Add to Collection

Article Cell Biology

BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions

Danfeng Zhang et al.

Summary: Multiple myeloma is a malignancy characterized by plasma cell accumulation in the bone marrow. Within the tumor microenvironment, macrophages in multiple myeloma exhibit pro-myeloma functions, which are modulated by the polycomb-group protein BMI1. Knockout of BMI1 in MM-associated macrophages leads to reduced proliferation, decreased expression of angiogenic factors, and loss of protection against chemotherapy-induced cell death, ultimately negating the pro-myeloma effects of these cells.

CELL DEATH & DISEASE (2021)

Add to Collection

Review Immunology

Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes

Tiffany Davia Ricketts et al.

Summary: This article discusses the roles of macrophages in tumors, with tumors exploiting macrophage characteristics to promote tumor growth. By preventing macrophages from adopting a pro-tumor phenotype or reprogramming them to a pro-inflammatory state, it may be possible to inhibit tumor growth.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Hematology

Cereblon enhancer methylation and IMiD resistance in multiple myeloma

Larissa Haertle et al.

Summary: It has been discovered that aberrant CRBN DNA methylation is a novel mechanism of IMiD resistance in multiple myeloma patients. Demethylation of the CRBN enhancer can enhance the therapeutic effect of lenalidomide on MM cells.

BLOOD (2021)

Add to Collection

Article Oncology

Exosome-derived miR-let-7c promotes angiogenesis in multiple myeloma by polarizing M2 macrophages in the bone marrow microenvironment

Xiangyu Tian et al.

Summary: The research discovered that exosomal miR-let-7c affects angiogenesis and macrophage polarization in multiple myeloma, potentially serving as a biomarker for early tumor progression and a promising therapeutic target.

LEUKEMIA RESEARCH (2021)

Add to Collection

Review Oncology

The Role of Tumor-Associated Macrophages in Hematologic Malignancies

Emanuele Cencini et al.

Summary: Tumor-associated macrophages (TAM) play a crucial role in hematologic malignancies and their polarization status can affect patient outcomes.

CANCERS (2021)

Add to Collection

Article Oncology

Stromal Cells Serve Drug Resistance for Multiple Myeloma via Mitochondrial Transfer: A Study on Primary Myeloma and Stromal Cells

Zsolt Matula et al.

Summary: Mitochondrial transfer plays a crucial role in drug resistance acquisition in multiple myeloma, with bi-directional transfer occurring through tunneling nanotubes and partial cell fusion, especially under the influence of chemotherapeutic drugs. By influencing tumor metabolism and using oxidative phosphorylation inhibitors alongside chemotherapy, the supportive effect of stromal cells can be effectively avoided in myeloma cells.

CANCERS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model

I-Li Tan et al.

Summary: The immune microenvironment of tumors plays a critical role in tumor progression, with TAMs promoting SHH-MB progression in a mouse model. Inhibiting CSF1R reduces TAMs, prolongs survival, and decreases tumor volume, suggesting therapeutic potential for SHH-MB patients.

ONCOGENE (2021)

Add to Collection

Article Hematology

JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression

Haiming Chen et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Review Immunology

The prognostic value of tumour-associated macrophages in Non-Hodgkin's lymphoma: A systematic review and meta-analysis

Xuanxuan Xu et al.

SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2020)

Add to Collection

Article Hematology

Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma

Nasrin Rastgoo et al.

HAEMATOLOGICA (2020)

Add to Collection

Article Oncology

The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia

Zi-Jun Xu et al.

ONCOIMMUNOLOGY (2020)

Add to Collection

Article Hematology

Phenotypic characterization of macrophages in the BMB sample of human acute leukemia

Jian-Xin Song et al.

ANNALS OF HEMATOLOGY (2020)

Add to Collection

Article Oncology

Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma

Jennifer Sun et al.

CANCERS (2020)

Add to Collection

Article Hematology

CD14+CD16+monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy

Paola Storti et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Review Oncology

Just eat it: A review of CD47 and SIRP-alpha antagonism

Bryan Oronsky et al.

SEMINARS IN ONCOLOGY (2020)

Add to Collection

Article Hematology

Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma

Saeko Kuwahara-Ota et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Review Immunology

Determinants of Resident Tissue Macrophage Identity and Function

Camille Bleriot et al.

IMMUNITY (2020)

Add to Collection

Review Medicine, General & Internal

Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients

Roberto Ria et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Review Oncology

Role of CD47 in Hematological Malignancies

Entsar Eladl et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection

Article Oncology

Correlation of APE1 with VEGFA and CD163+macrophage infiltration in bladder cancer and their prognostic significance

Lin-Ang Wang et al.

ONCOLOGY LETTERS (2020)

Add to Collection

Article Oncology

Synergistic effects of multiple myeloma cells and tumor-associated macrophages on vascular endothelial cells in vitro

Miaomiao Sun et al.

MEDICAL ONCOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Cytokine profile in multiple myeloma

Shivali Jasrotia et al.

CYTOKINE (2020)

Add to Collection

Article Oncology

Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients

Alessandro Gozzetti et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Oncology

A Prospective Study of Circulating Chemokines and Angiogenesis Markers and Risk of Multiple Myeloma and Its Precursor

Jonathan N. Hofmann et al.

JNCI CANCER SPECTRUM (2020)

Add to Collection

Article Oncology

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma

Konstantinos Papadimitriou et al.

CANCERS (2020)

Add to Collection

Article Integrative & Complementary Medicine

Frankincense and myrrh and their bioactive compounds ameliorate the multiple myeloma through regulation of metabolome profiling and JAK/STAT signaling pathway based on U266 cells

Rumeng Gao et al.

BMC COMPLEMENTARY MEDICINE AND THERAPIES (2020)

Add to Collection

Article Oncology

Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma

Oksana Zavidij et al.

NATURE CANCER (2020)

Add to Collection

Article Oncology

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma

Maria Cuce et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Macrophage chemoattractants secreted by cancer cells: Sculptors of the tumor microenvironment and another crucial piece of the cancer secretome as a therapeutic target

Nese Unver

CYTOKINE & GROWTH FACTOR REVIEWS (2019)

Add to Collection

Article Cell Biology

Acute Lymphoblastic Leukaemia Cells Impair Dendritic Cell and Macrophage Differentiation: Role of BMP4

Jaris Valencia et al.

CELLS (2019)

Add to Collection

Article Oncology

Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy

Ofrat Beyar-Katz et al.

MOLECULAR CANCER RESEARCH (2019)

Add to Collection

Article Oncology

Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo

Khatora S. Opperman et al.

NEOPLASIA (2019)

Add to Collection

Article Cell Biology

CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma

Ruyi Xu et al.

CELL DEATH & DISEASE (2019)

Add to Collection

Article Oncology

Multiple myeloma cell-derived IL-32γ increases the immunosuppressive function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression

Haimeng Yan et al.

CANCER LETTERS (2019)

Add to Collection

Article Oncology

High numbers of CD163+tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens

Hua Wang et al.

JOURNAL OF CANCER (2019)

Add to Collection

Article Oncology

Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma

Q. Wang et al.

LEUKEMIA (2018)

Add to Collection

Article Oncology

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma

A. Besse et al.

LEUKEMIA (2018)

Add to Collection

Review Hematology

Blocking don't eat me signal of CD47-SIRPα in hematological malignancies, an in-depth review

Atlantis Russ et al.

BLOOD REVIEWS (2018)

Add to Collection

Article Cell Biology

Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells

Bolun Wang et al.

CELL CYCLE (2018)

Add to Collection

Review Biochemistry & Molecular Biology

The good and bad faces of the CXCR4 chemokine receptor

Joaquin Teixido et al.

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2018)

Add to Collection

Review Biochemistry & Molecular Biology

Macrophages: The Road Less Traveled, Changing Anticancer Therapy

Jennifer L. Guerriero

TRENDS IN MOLECULAR MEDICINE (2018)

Add to Collection

Article Oncology

The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma

Sara Canovas Nunes et al.

BLOOD CANCER JOURNAL (2018)

Add to Collection

Article Immunology

Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma

Manh-Cuong Vo et al.

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection

Review Immunology

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance

Niels W. C. J. van de Donk et al.

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection

Article Cell Biology

MicroRNA-342 inhibits tumor growth via targeting chemokine CXCL12 involved in macrophages recruitment/activation

Yijun Tian et al.

GENES TO CELLS (2018)

Add to Collection

Article Medicine, General & Internal

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma

Ranjana Advani et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Hematology

Potential anti-lymphoma effect of M-CSFR inhibitor in adult T-cell leukemia/lymphoma

Yoshihiro Komohara et al.

JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY (2018)

Add to Collection

Article Oncology

Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment

Emanuele Cencini et al.

HEMATOLOGICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes

Jingxuan Wang et al.

ONCOTARGET (2017)

Add to Collection

Letter Oncology

Prognostic role of M2 tumour-associated macrophages in lymphoproliferative disorders

Emanuele Cencini et al.

JOURNAL OF PATHOLOGY (2017)

Add to Collection

Article Oncology

Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation

Nathan De Beule et al.

JOURNAL OF PATHOLOGY (2017)

Add to Collection

Review Oncology

Tumour-associated macrophages as treatment targets in oncology

Alberto Mantovani et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2017)

Add to Collection

Article Biology

IL-6 Mediates Macrophage Infiltration after Irradiation via Up-regulation of CCL2/CCL5 in Non-small Cell Lung Cancer

Xin Wang et al.

RADIATION RESEARCH (2017)

Add to Collection

Article Cell Biology

BAFF is involved in macrophage-induced bortezomib resistance in myeloma

Jing Chen et al.

CELL DEATH & DISEASE (2017)

Add to Collection

Article Oncology

Prognostic value of diametrically polarized tumor- associated macrophages in multiple myeloma

Xinyi Chen et al.

ONCOTARGET (2017)

Add to Collection

Article Oncology

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma

Xiaoyan Feng et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Letter Oncology

Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma

S. Panchabhai et al.

LEUKEMIA (2016)

Add to Collection

Article Oncology

Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo

B. S. Hanna et al.

LEUKEMIA (2016)

Add to Collection

Article Pathology

Prognostic Impact of Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Uniformly Treated With R-CHOP Chemotherapy

Juan C. Gomez-Gelvez et al.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2016)

Add to Collection

Article Hematology

Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma

Alejandra Gutierrez-Gonzalez et al.

BLOOD (2016)

Add to Collection

Article Hematology

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

K. Martin Kortum et al.

BLOOD (2016)

Add to Collection

Article Hematology

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Jakub Krejcik et al.

BLOOD (2016)

Add to Collection

Article Oncology

Targeting vasculogenesis to prevent progression in multiple myeloma

M. Moschetta et al.

LEUKEMIA (2016)

Add to Collection

Review Oncology

Role of interleukin-6 in cancer progression and therapeutic resistance

Neeraj Kumari et al.

TUMOR BIOLOGY (2016)

Add to Collection

Article Immunology

Induction of Monocyte Chemoattractant Proteins in Macrophages via the Production of Granulocyte/Macrophage ColonyStimulating Factor by Breast Cancer Cells

Teizo Yoshimura et al.

FRONTIERS IN IMMUNOLOGY (2016)

Add to Collection

Article Oncology

The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association

Robert Kridel et al.

CLINICAL CANCER RESEARCH (2015)

Add to Collection

Article Immunology

CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages

Takanori Kitamura et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2015)

Add to Collection

Article Oncology

Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma

Thanh-Nhan Nguyen-Pham et al.

JOURNAL OF IMMUNOTHERAPY (2015)

Add to Collection

Article Oncology

Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow

T. Matthes et al.

LEUKEMIA (2015)

Add to Collection

Article Oncology

The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): Implications in multiple myeloma

Morten N. Andersen et al.

LEUKEMIA RESEARCH (2015)

Add to Collection

Article Oncology

Interleukin-10 Induces Both Plasma Cell Proliferation and Angiogenesis in Multiple Myeloma

Michael G. Alexandrakis et al.

PATHOLOGY & ONCOLOGY RESEARCH (2015)

Add to Collection

Article Oncology

Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi Macrophage-Derived VEGFA

Allison S. Harney et al.

CANCER DISCOVERY (2015)

Add to Collection

Article Oncology

Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma

Yi Li et al.

ONCOTARGET (2015)

Add to Collection

Article Oncology

Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma

Jeffrey Lee Jensen et al.

CANCER IMMUNOLOGY RESEARCH (2015)

Add to Collection

Review Immunology

Anatomy of a discovery: M1 and M2 macrophages

Charles Dudley Mills

FRONTIERS IN IMMUNOLOGY (2015)

Add to Collection

Article Oncology

Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma

Arianna Calcinotto et al.

ONCOIMMUNOLOGY (2015)

Add to Collection

Article Hematology

Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia

Valentina Audrito et al.

BLOOD (2015)

Add to Collection

Review Oncology

The role of P-glycoprotein in drug resistance in multiple myeloma

Joseph Abraham et al.

LEUKEMIA & LYMPHOMA (2015)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

The Good, the Bad, and the Ugly of interleukin-6 signaling

Jose J. Fuster et al.

EMBO JOURNAL (2014)

Add to Collection

Article Hematology

Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma

Morten N. Andersen et al.

EUROPEAN JOURNAL OF HAEMATOLOGY (2014)

Add to Collection

Article Biochemistry & Molecular Biology

Bone marrow vascular niche and the control of angiogenesis in multiple myeloma

Domenico Ribatti et al.

FRONTIERS IN BIOSCIENCE-LANDMARK (2014)

Add to Collection

Article Immunology

Transcriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation

Jia Xue et al.

IMMUNITY (2014)

Add to Collection

Article Multidisciplinary Sciences

Functional polarization of tumour-associated macrophages by tumour-derived lactic acid

Oscar R. Colegio et al.

NATURE (2014)

Add to Collection

Article Immunology

Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin

Jan Mauer et al.

NATURE IMMUNOLOGY (2014)

Add to Collection

Article Biochemistry & Molecular Biology

Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs

Philip P. Chamberlain et al.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)

Add to Collection

Article Hematology

Microenvironment and multiple myeloma spread

Domenico Ribatti et al.

THROMBOSIS RESEARCH (2014)

Add to Collection

Article Oncology

Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype

Katia Beider et al.

ONCOTARGET (2014)

Add to Collection

Review Oncology

Therapeutic advancements in multiple myeloma

Alessandro Gozzetti et al.

FRONTIERS IN ONCOLOGY (2014)

Add to Collection

Article Peripheral Vascular Disease

Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma

Annunziata De Luisi et al.

ANGIOGENESIS (2013)

Add to Collection

Article Hematology

Tumor-associated macrophages as a prognostic parameter in multiple myeloma

Elif Suyani et al.

ANNALS OF HEMATOLOGY (2013)

Add to Collection

Article Oncology

A Human ICAM-1 Antibody Isolated by a Function-First Approach Has Potent Macrophage-Dependent Antimyeloma Activity In Vivo

Niina Veitonmaki et al.

CANCER CELL (2013)

Add to Collection

Article Oncology

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

Chungyee Leung-Hagesteijn et al.

CANCER CELL (2013)

Add to Collection

Review Oncology

Macrophage plasticity and polarization in tissue repair and remodelling

Alberto Mantovani et al.

JOURNAL OF PATHOLOGY (2013)

Add to Collection

Article Oncology

PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma

Y. Zheng et al.

LEUKEMIA (2013)

Add to Collection

Article Oncology

Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma

D. Azambuja et al.

ANNALS OF ONCOLOGY (2012)

Add to Collection

Article Immunology

TGFβ signaling plays a critical role in promoting alternative macrophage activation

Dapeng Gong et al.

BMC IMMUNOLOGY (2012)

Add to Collection

Article Hematology

Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells

Jaehyup Kim et al.

BRITISH JOURNAL OF HAEMATOLOGY (2012)

Add to Collection

Article Oncology

Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients

Alessandro Gozzetti et al.

CANCER (2012)

Add to Collection

Article Medicine, Research & Experimental

Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma

Giuseppina Bonanno et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2012)

Add to Collection

Article Oncology

Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells

D. Kim et al.

LEUKEMIA (2012)

Add to Collection

Article Biochemistry & Molecular Biology

IL-6-induced Enhancement of c-Myc Translation in Multiple Myeloma Cells CRITICAL ROLE OF CYTOPLASMIC LOCALIZATION OF THE RNA-BINDING PROTEIN hnRNP A1

Yijiang Shi et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2011)

Add to Collection

Article Oncology

Alternative methods of cladribine administration

Francesco Lauria et al.

LEUKEMIA & LYMPHOMA (2011)

Add to Collection

Article Immunology

Tumor-Conditioned Macrophages Secrete Migration-Stimulating Factor: A New Marker for M2-Polarization, Influencing Tumor Cell Motility

Graziella Solinas et al.

JOURNAL OF IMMUNOLOGY (2010)

Add to Collection

Review Oncology

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

H. Quach et al.

LEUKEMIA (2010)

Add to Collection

Article Oncology

Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells?

Eva Kovacs

LEUKEMIA RESEARCH (2010)

Add to Collection

Article Medicine, General & Internal

Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma

Christian Steidl et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection

Article Hematology

Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis

Haiming Chen et al.

BLOOD (2009)

Add to Collection

Article Hematology

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy

Abdel Kareem Azab et al.

BLOOD (2009)

Add to Collection

Article Hematology

Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis

Yuhuan Zheng et al.

BLOOD (2009)

Add to Collection

Article Oncology

Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Myeloma: Kinetics of Neutropenia and Thrombocytopenia and Time-to-Event Results

Antonio Palumbo et al.

CLINICAL LYMPHOMA & MYELOMA (2009)

Add to Collection

Article Biochemistry & Molecular Biology

Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma

C. Scavelli et al.

ONCOGENE (2008)

Add to Collection

Article Hematology

Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma

Jannie M. Rendtlew Danielsen et al.

BRITISH JOURNAL OF HAEMATOLOGY (2007)

Add to Collection

Review Hematology

Chemokines in multiple myeloma

Rohit Aggarwal et al.

EXPERIMENTAL HEMATOLOGY (2006)

Add to Collection

Review Biochemistry & Molecular Biology

Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma

D. Ribatti et al.

ONCOGENE (2006)

Add to Collection

Review Oncology

Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy

A Sica et al.

EUROPEAN JOURNAL OF CANCER (2006)

Add to Collection

Review Oncology

Role of tumor-associated macrophages in tumor progression and invasion

Alberto Mantovani et al.

CANCER AND METASTASIS REVIEWS (2006)

Add to Collection

Article Hematology

Macrophage inflammatory protein 1-alpha (MIP-1α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells

S Lentzsch et al.

BLOOD (2003)

Add to Collection

Article Oncology

Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1,-2 and-3

IV Broek et al.

BRITISH JOURNAL OF CANCER (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.